Skip to main navigation
Close
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Legislation
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Resources
All Resources
2022 Savings Report
2022 Interactive State Savings Map
2022 Voices of Access Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Supply Chain Blueprint
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Menu
Interactive Savings Map
- Find out how much your state saved from generic and biosimilar medicines.
Learn More
Close
Breadcrumb
Association for Accessible Medicines
Resources
Blog
Blog
Share
Blog
Jul 28, 2022
| Dan Leonard
AAM All Access Podcast: Medicare Drug Price Negotiation is Bad for Patients
Blog
Jul 25, 2022
| Craig Burton
Drug Price Negotiation Proposals Undermine Current Bipartisan Approaches to Lower Drug Spending
Blog
Jul 21, 2022
| Dan Leonard
AAM All Access Podcast: CMMB’s Urgent Mission
Blog
Jul 20, 2022
| Craig Burton
The Evidence Is Clear: Biosimilar Competition Will Achieve More Savings for Patients Than Build Back Better’s Negotiations
Blog
Jul 20, 2022
| Craig Burton
Medicare Negotiations Serve as a Catalyst to a Perpetual Monopoly
Blog
Jul 20, 2022
| Craig Burton
Proposed BBB Negotiation Framework Discourages Biosimilar Competition, Imposes Higher Costs on Commercially Insured Patients and Their Employers
Blog
Jul 12, 2022
| Monét Stanford
Despite Enrollment In Medicare Prescription Drug Coverage, Over Half of All Seniors Pay Full Cost for Many Generic Drugs
Blog
Jul 1, 2022
| Dan Leonard
AAM All Access Podcast: Drug Shortages and the U.S. Supply Chain
Blog
May 31, 2022
| Erica Klinger
Everything You Need to Know About Biosimilars – All in One Place
Blog
May 23, 2022
| Monét Stanford
AAM Calls for Federal Trade Commission to Investigate PBM Business Practices
Blog
May 2, 2022
| Monét Stanford
Generics Drive Savings Yet Patients Continue to Pay More
Blog
Apr 19, 2022
| Monét Stanford
As Health Care Spending in US Projected to Increase, Generics and Biosimilars Expected to Moderate Growth
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Legislation
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
GRx+Biosims 2022
Access! 2022
Resources
All Resources
2022 Savings Report
2022 Interactive State Savings Map
2022 Voices of Access Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Supply Chain Blueprint
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action